Shockwave Medical Inc. (NASDAQ:SWAV)

Total inventory levels exhibited a consistent and aggressive upward trajectory between 2019 and 2023, increasing from $12.1 million to $107.6 million. This represents a nearly ninefold increase over the five-year period, indicating a significant scaling of operational capacity and a substantial increase in working capital allocation toward inventory.

Raw Materials Growth

Raw material holdings grew steadily from $2.5 million in 2019 to $25.7 million in 2023. A notable acceleration in accumulation occurred between 2021 and 2022, where the value increased by approximately 139%, suggesting a strategic shift toward securing a larger supply of inputs to support expanded production.

Work in Progress Volatility

Work in progress (WIP) demonstrated a non-linear growth pattern. After an initial climb from $1.4 million in 2019 to a peak of $13.3 million in 2021, a contraction to $7.7 million was observed in 2022. However, this was followed by a sharp recovery to $16.5 million in 2023, indicating fluctuations in production cycles or shifts in manufacturing efficiency during the 2022 period.

Finished Goods Accumulation

Finished goods represent the largest component of the total inventory across all reported years. The value increased from $8.2 million in 2019 to $65.4 million in 2023. The most significant surge occurred between 2021 and 2022, with the balance more than doubling, reflecting an increase in available stock to meet projected market demand.

Inventory Composition Analysis

The composition of inventory has shifted over time. In 2019, finished goods accounted for approximately 68% of total inventory. By 2023, while finished goods remained the dominant category, they represented approximately 61% of the total, while raw materials increased their share from 21% in 2019 to 24% in 2023. This shift suggests a more balanced investment across the production pipeline to mitigate supply chain risks.